FÃ©lix Javier JimÃ©nez-JimÃ©nez

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6012577/publications.pdf

Version: 2024-02-01

139 papers	3,962 citations	109321 35 h-index	168389 53 g-index
149 all docs	149 docs citations	149 times ranked	4273 citing authors

#	Article	IF	Citations
1	Serum Trace Elements Concentrations in Patients with Restless Legs Syndrome. Antioxidants, 2022, 11, 272.	5.1	7
2	Association of Essential Tremor With Novel Risk Loci. JAMA Neurology, 2022, 79, 185.	9.0	17
3	Increased serum diamine oxidase activity in nonallergic patients with migraine. European Journal of Clinical Investigation, 2022, 52, e13757.	3.4	10
4	Vitamin D Receptor and Binding Protein Gene Variants in Patients with Essential Tremor. Molecular Neurobiology, 2022, , 1.	4.0	0
5	Coenzyme Q10 and Parkinsonian Syndromes: A Systematic Review. Journal of Personalized Medicine, 2022, 12, 975.	2.5	5
6	Cerebrospinal and blood levels of amino acids as potential biomarkers for Parkinson's disease: review and metaâ€analysis. Response to letter to the editor by Zheng et al.. European Journal of Neurology, 2021, 28, e13-e14.	3.3	2
7	Serum vitamin D, vitamin D receptor and binding protein genes polymorphisms in restless legs syndrome. Journal of Neurology, 2021, 268, 1461-1472.	3.6	7
8	Exome-wide rare variant analysis in familial essential tremor. Parkinsonism and Related Disorders, 2021, 82, 109-116.	2.2	11
9	Biological fluid levels of iron and ironâ€related proteins in Parkinsonâ€™s disease: Review and metaâ€analysis. European Journal of Neurology, 2021, 28, 1041-1055.	3.3	15
10	Common Endothelial Nitric Oxide Synthase Single Nucleotide Polymorphisms are not Related With the Risk for Restless Legs Syndrome. Frontiers in Pharmacology, 2021, 12, 618989.	3.5	3
11	Sleep Disorders in Patients with Essential Tremor. Current Neurology and Neuroscience Reports, 2021, 21, 23.	4.2	5
12	Association between restless legs syndrome and peripheral neuropathy: A systematic review and metaâ€analysis. European Journal of Neurology, 2021, 28, 2423-2442.	3.3	14
13	Genomic Markers for Essential Tremor. Pharmaceuticals, 2021, 14, 516.	3.8	16
14	Neurochemical Features of Rem Sleep Behaviour Disorder. Journal of Personalized Medicine, 2021, 11, 880.	2.5	10
15	Current Treatment Options for REM Sleep Behaviour Disorder. Journal of Personalized Medicine, 2021, 11, 1204.	2.5	6
16	Association between endothelial nitric oxide synthase (NOS3) rs2070744 and the risk for migraine. Pharmacogenomics Journal, 2020, 20, 426-432.	2.0	12
17	Anti-Inflammatory Effects of Amantadine and Memantine: Possible Therapeutics for the Treatment of Covid-19?. Journal of Personalized Medicine, 2020, 10, 217.	2.5	25
18	Cerebrospinal and blood levels of amino acids as potential biomarkers for Parkinsonâ€™s disease: review and metaâ€analysis. European Journal of Neurology, 2020, 27, 2336-2347.	3.3	26

#	Article	IF	Citations
19	Endothelial nitric oxide synthase (NOS3) rs2070744 polymorphism and risk for multiple sclerosis. Journal of Neural Transmission, 2020, 127, 1167-1175.	2.8	6
20	Sleep disorders in essential tremor: systematic review and meta-analysis. Sleep, 2020, 43, .	1.1	15
21	Sleep disorders in tourette syndrome. Sleep Medicine Reviews, 2020, 53, 101335.	8.5	25
22	An Update on the Neurochemistry of Essential Tremor. Current Medicinal Chemistry, 2020, 27, 1690-1710.	2.4	8
23	Current and Future Neuropharmacological Options for the Treatment of Essential Tremor. Current Neuropharmacology, 2020, 18, 518-537.	2.9	20
24	The Relationship Between Parkinsonâ€™s Disease and Essential Tremor: Review of Clinical, Epidemiologic, Genetic, Neuroimaging and Neuropathological Data, and Data on the Presence of Cardinal Signs of Parkinsonism in Essential Tremor. Tremor and Other Hyperkinetic Movements, 2020, 2, 02.	2.0	11
25	Hereditary Coproporphyria Associated with the Q306X Mutation in the Coproporphyrin Oxidase Gene Presenting with Acute Ataxia. Tremor and Other Hyperkinetic Movements, 2020, 3, 03.	2.0	3
26	Association between restless legs syndrome and other movement disorders. Neurology, 2019, 92, 948-964.	1.1	45
27	Neurochemical features of idiopathic restless legs syndrome. Sleep Medicine Reviews, 2019, 45, 70-87.	8.5	31
28	Alcohol consumption and risk for Parkinsonâ€™s disease: a systematic review and meta-analysis. Journal of Neurology, 2019, 266, 1821-1834.	3.6	27
29	Peroneal nerve mononeuropathy associated with herpes zoster. A case report. Neurological Sciences, 2019, 40, 847-850.	1.9	0
30	Association between the missense alcohol dehydrogenase rs1229984T variant with the risk for Parkinsonâ€™s disease in women. Journal of Neurology, 2019, 266, 346-352.	3.6	14
31	Gamma-aminobutyric acid (GABA) receptors GABRA4, GABRE, and GABRQ gene polymorphisms and risk for migraine. Journal of Neural Transmission, 2018, 125, 689-698.	2.8	14
32	Gamma-aminobutyric acid (GABA) receptors genes polymorphisms and risk for restless legs syndrome. Pharmacogenomics Journal, 2018, 18, 565-577.	2.0	18
33	Genetics of restless legs syndrome: An update. Sleep Medicine Reviews, 2018, 39, 108-121.	8.5	78
34	Missense Gamma-Aminobutyric Acid Receptor Polymorphisms Are Associated with Reaction Time, Motor Time, and Ethanol Effects in Vivo. Frontiers in Cellular Neuroscience, 2018, 12, 10.	3.7	6
35	Deltaâ€aminoâ€levulinic acid dehydratase gene and essential tremor. European Journal of Clinical Investigation, 2017, 47, 348-356.	3.4	4
36	Hypersexuality Possibly Associated With Safinamide. Journal of Clinical Psychopharmacology, 2017, 37, 635-636.	1.4	8

#	Article	IF	Citations
37	Gammaâ€Aminobutyric Acid (Gaba) Receptors Rho (Gabrr) Gene Polymorphisms and Risk for Migraine. Headache, 2017, 57, 1118-1135.	3.9	15
38	Thr105Ile (rs11558538) polymorphism in the histamine-1-methyl-transferase (HNMT) gene and risk for restless legs syndrome. Journal of Neural Transmission, 2017, 124, 285-291.	2.8	14
39	Association Between the rs1229984 Polymorphism in the Alcohol Dehydrogenase 1B Gene and Risk for Restless Legs Syndrome. Sleep, 2017, 40, .	1.1	14
40	Cataplexy Possibly Associated With Lamotrigine. Journal of Clinical Psychopharmacology, 2016, 36, 400-402.	1.4	4
41	Advances in understanding genomic markers and pharmacogenetics of Parkinsonâ€™s disease. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 433-448.	3.3	33
42	A family study of DRD3 rs6280, SLC1A2 rs3794087 and MAPT rs1052553 variants in essential tremor. Neurological Research, 2016, 38, 880-887.	1.3	8
43	Heme Oxygenase-1 and 2 Common Genetic Variants and Risk for Multiple Sclerosis. Scientific Reports, 2016, 6, 20830.	3.3	26
44	Thr105Ile (rs11558538) polymorphism in the histamine N-methyltransferase (HNMT) gene and risk for Parkinson disease. Medicine (United States), 2016, 95, e4147.	1.0	19
45	NAT2 polymorphisms and risk for Parkinsonâ€™s disease: a systematic review and meta-analysis. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 937-946.	3.3	6
46	An Update on the Role of Nitric Oxide in the Neurodegenerative Processes of Parkinson's Disease. Current Medicinal Chemistry, 2016, 23, 2666-2679.	2.4	51
47	Neuronal Nitric Oxide Synthase (<scp>nNOS</scp>, <scp>NOS</scp>1) rs693534 and rs7977109 Variants and Risk for Migraine. Headache, 2015, 55, 1209-1217.	3.9	18
48	Association Between Vitamin D Receptor rs731236 (Taq1) Polymorphism and Risk for Restless Legs Syndrome in the Spanish Caucasian Population. Medicine (United States), 2015, 94, e2125.	1.0	23
49	Heme Oxygenase-1 and 2 Common Genetic Variants and Risk for Restless Legs Syndrome. Medicine (United States), 2015, 94, e1448.	1.0	31
50	Neuronal nitric oxide synthase (nNOS, NOS1) rs693534 and rs7977109 variants and risk for restless legs syndrome. Journal of Neural Transmission, 2015, 122, 819-823.	2.8	23
51	Diamine Oxidaseâ€¦<scp>rs</scp>10156191 and <scp>rs</scp>2052129 Variants Are Associated With the Risk for Migraine. Headache, 2015, 55, 276-286.	3.9	49
52	Missense mutations inTENM4, a regulator of axon guidance and central myelination, cause essential tremor. Human Molecular Genetics, 2015, 24, 5677-5686.	2.9	134
53	TREM2 R47H variant and risk of essential tremor: A cross-sectional international multicenter study. Parkinsonism and Related Disorders, 2015, 21, 306-309.	2.2	28
54	The potential of LINGO-1 as a therapeutic target for essential tremor. Expert Opinion on Therapeutic Targets, 2015, 19, 1139-1148.	3.4	9

#	Article	IF	Citations
55	The GSTP1 gene variant rs1695 is not associated with an increased risk of multiple sclerosis. Cellular and Molecular Immunology, 2015, 12, 777-779.	10.5	5
56	Neurochemistry of Idiopathic Restless Legs Syndrome. European Neurological Review, 2015, 10, 35.	0.5	7
57	Treatment Options for Idiopathic Restless Legs Syndrome. European Neurological Review, 2015, 10, 45.	0.5	2
58	An association study between Heme oxygenase-1 genetic variants and Parkinson's disease. Frontiers in Cellular Neuroscience, 2014, 8, 298.	3.7	39
59	Drug and xenobiotic biotransformation in the bloodÃ¢â‚¬â€œbrain barrier: a neglected issue. Frontiers in Cellular Neuroscience, 2014, 8, 335.	3.7	37
60	Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease. Frontiers in Cellular Neuroscience, 2014, 8, 369.	3.7	68
61	<i>PITX3</i> and Risk for Parkinson's Disease: A Systematic Review and Meta-Analysis. European Neurology, 2014, 71, 49-56.	1.4	16
62	The solute carrier family 1 (glial high affinity glutamate transporter), member 2 gene, SLC1A2, rs3794087 variant and assessment risk for restless legs syndrome. Sleep Medicine, 2014, 15, 266-268.	1.6	22
63	SLC1A2 rs3794087 variant and risk for migraine. Journal of the Neurological Sciences, 2014, 338, 92-95.	0.6	13
64	NQO1gene rs1800566 variant is not associated with risk for multiple sclerosis. BMC Neurology, 2014, 14, 87.	1.8	10
65	Genomic and Pharmacogenomic Biomarkers of Parkinsonâ€™s Disease. Current Drug Metabolism, 2014, 15, 129-181.	1.2	47
66	LINGO1 rs9652490 and rs11856808 polymorphisms are not associated with risk for multiple sclerosis. BMC Neurology, 2013, 13, 34.	1.8	10
67	MAPT1 gene rs1052553 variant is unrelated with the risk for restless legs syndrome. Journal of Neural Transmission, 2013, 120, 463-467.	2.8	17
68	Fungal infection in cerebrospinal fluid from some patients with multiple sclerosis. European Journal of Clinical Microbiology and Infectious Diseases, 2013, 32, 795-801.	2.9	33
69	Dopamine receptor D3 (DRD3) gene rs6280 variant and risk for restless legs syndrome. Sleep Medicine, 2013, 14, 382-384.	1.6	16
70	Fused in Sarcoma (FUS) gene mutations are not a frequent cause of essential tremor in Europeans. Neurobiology of Aging, 2013, 34, 2441.e9-2441.e11.	3.1	22
71	MAPT gene rs1052553 variant is not associated with the risk for multiple sclerosis. Human Immunology, 2013, 74, 1705-1708.	2.4	4
72	Anti-Parkinson's disease drugs and pharmacogenetic considerations. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 859-874.	3.3	47

#	Article	IF	Citations
73	Update on genetics of essential tremor. Acta Neurologica Scandinavica, 2013, 128, 359-371.	2.1	41
74	Concentric visual field defect related to spontaneous intracranial hypotension. International Ophthalmology, 2013, 33, 583-587.	1.4	2
75	Vitamin D3 Receptor (VDR) Gene rs2228570 (Fok1) and rs731236 (Taq1) Variants Are Not Associated with the Risk for Multiple Sclerosis: Results of a New Study and a Meta-Analysis. PLoS ONE, 2013, 8, e65487.	2.5	57
76	Latest Perspectives in Genetic Risk Factors for Restless Legs Syndrome. European Neurological Review, 2013, 8, 90.	0.5	7
77	LINGO1 and risk for essential tremor: Results of a meta-analysis of rs9652490 and rs11856808. Journal of the Neurological Sciences, 2012, 317, 52-57.	0.6	39
78	Digital Voice Analysis in Patients With Advanced Parkinsonâ€™s Disease Undergoing Deep Brain Stimulation Therapy. Journal of Voice, 2012, 26, 496-501.	1.5	18
79	H1-MAPT and the Risk for Familial Essential Tremor. PLoS ONE, 2012, 7, e41581.	2.5	17
80	Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain. Frontiers in Genetics, 2012, 3, 273.	2.3	23
81	Spontaneous intracranial hypotension syndrome treated with a double epidural blood patch. Acta Anaesthesiologica Scandinavica, 2012, 56, 1332-1335.	1.6	10
82	The relationship between Parkinson's disease and essential tremor: review of clinical, epidemiologic, genetic, neuroimaging and neuropathological data, and data on the presence of cardinal signs of parkinsonism in essential tremor. Tremor and Other Hyperkinetic Movements, 2012, 2, .	2.0	15
83	Influence of age and gender in motor performance in healthy subjects. Journal of the Neurological Sciences, 2011, 302, 72-80.	0.6	62
84	Gamma-aminobutyric acid GABRA4, GABRE, and GABRQ receptor polymorphisms and risk for essential tremor. Pharmacogenetics and Genomics, 2011, 21, 436-439.	1.5	28
85	Lack of association of LINGO1 rs9652490 and rs11856808 SNPs with familial essential tremor. European Journal of Neurology, 2011, 18, 1085-1089.	3.3	30
86	Gamma-aminobutyric acid (GABA) receptor rho (GABRR) polymorphisms and risk for essential tremor. Journal of Neurology, 2011, 258, 203-211.	3.6	28
87	Assessment of Parkinson Disease. Neurologist, 2011, 17, S21-S29.	0.7	5
88	Paraoxonase 1 (PON1) polymorphisms and risk for migraine. Journal of Neurology, 2010, 257, 1482-1485.	3.6	17
89	Paraoxonase 1 Polymorphisms Are Not Related with the Risk for Multiple Sclerosis. NeuroMolecular Medicine, 2010, 12, 217-223.	3.4	17
90	Oxidative stress in skin fibroblasts cultures from patients with Parkinson's disease. BMC Neurology, 2010, 10, 95.	1.8	37

#	Article	IF	Citations
91	Histamineâ€Nâ€methyl transferase polymorphism and risk for multiple sclerosis. European Journal of Neurology, 2010, 17, 335-338.	3.3	16
92	Impairment of rapid repetitive finger movements and visual reaction time in patients with essential tremor. European Journal of Neurology, 2010, 17, 152-159.	3.3	54
93	Paraoxonase 1 (PON1) polymorphisms and risk for essential tremor. European Journal of Neurology, 2010, 17, 879-881.	3.3	9
94	Dopamine receptor 3(DRD3) polymorphism and risk for migraine. European Journal of Neurology, 2010, 17, 1220-1223.	3.3	13
95	Frequency of CYP2D6 allelic variants in multiple sclerosis. Acta Neurologica Scandinavica, 2009, 92, 464-467.	2.1	8
96	Dopamine receptor D3 (DRD3) genotype and allelic variants and risk for essential tremor. Movement Disorders, 2009, 24, 1910-1915.	3.9	24
97	Motor performance in patients with restless legs syndrome. Movement Disorders, 2009, 24, 1656-1661.	3.9	6
98	The Nonsynonymous Thr105Ile Polymorphism of the Histamine N-Methyltransferase is Associated to the Risk of Developing Essential Tremor. NeuroMolecular Medicine, 2008, 10, 356-361.	3.4	23
99	Histamineâ€Nâ€Methyl Transferase Polymorphism and Risk for Migraine. Headache, 2008, 48, 1343-1348.	3.9	23
100	Glutathione-S-transferase P1 polymorphism and risk for essential tremor. European Journal of Neurology, 2008, 15, 234-238.	3.3	18
101	Voice tremor in monozygotic twins. European Journal of Neurology, 2008, 15, e80.	3.3	1
102	Hemimasticatory Spasm Secondary to Biopercular Syndrome. European Neurology, 2008, 59, 276-279.	1.4	19
103	Environmental Risk Factors for Essential Tremor. European Neurology, 2007, 58, 106-113.	1.4	53
104	Changes at the CYP2C locus and disruption of CYP2C8/9 linkage disequilibrium in patients with essential tremor. NeuroMolecular Medicine, 2007, 9, 195-204.	3.4	16
105	Alcohol Dehydrogenase 2 Genotype and Allelic Variants Are Not Associated With the Risk for Essential Tremor. Clinical Neuropharmacology, 2007, 30, 196-200.	0.7	19
106	<i>CYP2C19</i> Polymorphism and Risk for Essential Tremor. European Neurology, 2006, 56, 119-123.	1.4	29
107	Tau protein concentrations in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neurologica Scandinavica, 2005, 111, 114-117.	2.1	34
108	Drug-Induced Myoclonus. CNS Drugs, 2004, 18, 93-104.	5.9	59

#	Article	IF	Citations
109	Possible role of nondopaminergic drugs on levodopa-induced dyskinesias in Parkinsonâ€™s disease. Expert Review of Neurotherapeutics, 2002, 2, 427-431.	2.8	1
110	Familial Focal Dystonia. European Neurology, 2002, 48, 232-234.	1.4	8
111	Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis. Acta Neurologica Scandinavica, 2002, 106, 351-354.	2.1	42
112	Possible zoophilia associated with dopaminergic therapy in Parkinson disease. Annals of Pharmacotherapy, 2002, 36, 1178-9.	1.9	26
113	Pharmacological Options for the Treatment of Tourette??s Disorder. Drugs, 2001, 61, 2207-2220.	10.9	52
114	Pathologic gambling in Parkinson's disease: A behavioral manifestation of pharmacologic treatment?. Movement Disorders, 2000, 15, 869-872.	3.9	284
115	Hypnic Headache Associated With Stage 3 Slow Wave Sleep. Headache, 2000, 40, 753-754.	3.9	49
116	Serum levels of coenzyme Q10 in patients with Parkinson's disease. Journal of Neural Transmission, 2000, 107, 0177-0181.	2.8	46
117	Normal cerebrospinal fluid levels of insulin in patients with Parkinson's disease. Journal of Neural Transmission, 2000, 107, 445-449.	2.8	12
118	Reversible bitemporal hemianopsioa related to iatrogenic intracranial hypotension. Journal of Neurology, 2000, 247, 461-462.	3.6	2
119	Extrapyramidal Symptoms Associated with Selective Serotonin Reuptake Inhibitors. CNS Drugs, 2000, 14, 367-379.	5.9	12
120	Cerebrospinal Fluid Nitrate Levels in Patients with Multiple Sclerosis. European Neurology, 1999, 41, 44-47.	1.4	22
121	Serum levels of Î²â€carotene, Î±â€carotene and vitamin A in patients with Alzheimer's disease. European Journal of Neurology, 1999, 6, 495-497.	3.3	71
122	Fluctuating penile erection related with levodopa therapy. Neurology, 1999, 52, 210.	1.1	16
123	Cerebrospinal fluid levels of transition metals in patients with Parkinson's disease. Journal of Neural Transmission, 1998, 105, 497.	2.8	133
124	Cerebrospinal fluid levels of alpha-tocopherol in patients with multiple sclerosis. Neuroscience Letters, 1998, 249, 65-67.	2.1	34
125	The Role of Nitric Oxide in Neurodegeneration. Drugs and Aging, 1998, 12, 251-259.	2.7	63
126	Olanzapine can worsen parkinsonism. Neurology, 1998, 50, 1183-1184.	1.1	80

#	Article	IF	Citations
127	Slow allotypic variants of the NAT2 gene and susceptibility to early-onset Parkinson's disease. Neurology, 1998, 51, 1587-1592.	1.1	46
128	CYP2D6Polymorphism Is Not Associated with Essential Tremor. European Neurology, 1997, 38, 99-104.	1.4	20
129	Decreased cerebrospinal fluid levels of neutral and basic amino acids in patients with Parkinson's disease. Journal of the Neurological Sciences, 1997, 150, 123-127.	0.6	95
130	Clinical features of essential tremor seen in neurology practice: a study of 357 patients. Parkinsonism and Related Disorders, 1997, 3, 187-190.	2.2	41
131	Nicardipine improves motor tics. European Journal of Neurology, 1997, 4, 498-501.	3.3	2
132	Neurotransmitter amino acids in cerebrospinal fluid of patients with Parkinson's disease. Journal of the Neurological Sciences, 1996, 141, 39-44.	0.6	56
133	Decreased serum selenium concentrations in patients with Parkinson's disease. European Journal of Neurology, 1995, 2, 111-114.	3.3	17
134	Association between the oxidative polymorphism and early onset of Parkinson's disease*. Clinical Pharmacology and Therapeutics, 1995, 57, 291-298.	4.7	65
135	Peripheral iron metabolism in patients with Parkinson's disease. Journal of the Neurological Sciences, 1994, 125, 82-86.	0.6	28
136	Risk-factors for Parkinson's disease: case-control study in the province of CÃ¡ceres, Spain. Acta Neurologica Scandinavica, 1994, 89, 164-170.	2.1	138
137	Premorbid smoking, alcohol consumption, and coffee drinking habits in Parkinson's disease: A case-control study. Movement Disorders, 1992, 7, 339-344.	3.9	88
138	Acute Effects of 1-Methyl-4-Phenyl-1, 2, 3, 6-Tetrahydropyridine in a Model of Rat Designated a Poor Metabolizer of Debrisoquine. Journal of Neurochemistry, 1991, 57, 81-87.	3.9	39
139	Oxidative polymorphism of debrisoquine in Parkinson's disease.. Journal of Neurology, Neurosurgery and Psychiatry, 1990, 53, 289-292.	1.9	35